Diabetic Retinopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Diabetic Retinopathy Drugs Market Report Overview
Diabetic retinopathy is a complication of diabetes that affects the eyes. The symptoms may include spots or dark strings floating in vision (floaters), blurred vision, fluctuating vision, vision loss, and difficulty with color perception. The Diabetic Retinopathy pipeline drugs market research report provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.
| Key Targets | Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor), Placenta Growth Factor, Melanocyte Stimulating Hormone Receptor, Angiopoietin 1 Receptor, Integrin Alpha V, Integrin Beta 3, Melanocortin Receptor 5, Semaphorin 3A, and ADP Ribosylation Factor 6 |
| Key Mechanisms of Action | Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Melanocyte Stimulating Hormone Receptor Agonist, Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Melanocortin Receptor 5 Agonist, Semaphorin 3A Inhibitor, ADP Ribosylation Factor 6 Inhibitor, and Angiopoietin 1 Receptor Agonist |
| Key Routes of Administration | Intravitreal, Oral, Ophthalmic, Topical, Intravenous, Intraocular, Parenteral, Subcutaneous, Subconjunctival, and Buccal |
| Key Molecule Types | Small Molecule, Monoclonal Antibody, Fusion Protein, Synthetic Peptide, Biologic, Cell Therapy, Gene Therapy, Antisense RNAi Oligonucleotide, Recombinant Protein, and Aptamer |
| Leading Companies | F. Hoffmann-La Roche Ltd, Palatin Technologies Inc, Boehringer Ingelheim International GmbH, PharmAbcine Inc, Regeneron Pharmaceuticals Inc, A6 Pharmaceuticals LLC, Angios GmbH, Ascentage Pharma Group International, Bayer AG, and Charlesson LLC |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Diabetic Retinopathy Pipeline Drugs Market Segmentation by Targets
Some of the key targets of the Diabetic Retinopathy pipeline drugs market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor), Placenta Growth Factor, Melanocyte Stimulating Hormone Receptor, Angiopoietin 1 Receptor, Integrin Alpha V, Integrin Beta 3, Melanocortin Receptor 5, Semaphorin 3A, and ADP Ribosylation Factor 6. In 2022, Vascular Endothelial Growth Factor A emerged as the most adopted target in the diabetic retinopathy pipeline drugs market.
Diabetic Retinopathy Pipeline Drugs Market Analysis by Targets, 2022 (%)
For more Diabetic Retinopathy pipeline drugs market target insights, download a free report sample
Diabetic Retinopathy Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the Diabetic Retinopathy pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Melanocyte Stimulating Hormone Receptor Agonist, Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Melanocortin Receptor 5 Agonist, Semaphorin 3A Inhibitor, ADP Ribosylation Factor 6 Inhibitor, and Angiopoietin 1 Receptor Agonist. In 2022, Vascular Endothelial Growth Factor A Inhibitor is the most adopted mechanism of action in the diabetic retinopathy pipeline drugs market.
Diabetic Retinopathy Pipeline Drugs Market Analysis by Mechanisms of Action, 2022 (%)
For more mechanism of action insights into the Diabetic Retinopathy pipeline drugs market, download a free report sample
Diabetic Retinopathy Pipeline Drugs Market Segmentation by Routes of Administration
Some of the key routes of administration in the Diabetic Retinopathy pipeline drugs market are intravitreal, oral, ophthalmic, topical, intravenous, intraocular, parenteral, subcutaneous, subconjunctival, and buccal. In 2022, the most prominent route of administration for the diabetic retinopathy pipeline drugs market is intravitreal RoA.
Diabetic Retinopathy Pipeline Drugs Market Analysis by Routes of Administration, 2022 (%)
For more routes of administration insights into the Diabetic Retinopathy pipeline drugs market, download a free report sample
Diabetic Retinopathy Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Diabetic Retinopathy pipeline drugs market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, biologic, cell therapy, gene therapy, antisense RNAi oligonucleotide, recombinant protein, and aptamer. In 2022, the majority of the molecule types in the market are small molecules.
Diabetic Retinopathy Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)
For more molecule type insights into the Diabetic Retinopathy pipeline drugs market, download a free report sample
Diabetic Retinopathy Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Diabetic Retinopathy pipeline drugs market are F. Hoffmann-La Roche Ltd, Palatin Technologies Inc, Boehringer Ingelheim International GmbH, PharmAbcine Inc, Regeneron Pharmaceuticals Inc, A6 Pharmaceuticals LLC, Angios GmbH, Ascentage Pharma Group International, Bayer AG, and Charlesson LLC. In 2022, F. Hoffmann-La Roche Ltd emerged as the leading company with the highest number of pipeline drugs.
Diabetic Retinopathy Pipeline Drugs Market Analysis by Companies, 2022 (%)
To know more about the companies in the Diabetic Retinopathy pipeline drugs market, download a free report sample
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- Reviews of pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- Evaluation of Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the key targets of the Diabetic Retinopathy pipeline drugs market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor), Placenta Growth Factor, Melanocyte Stimulating Hormone Receptor, Angiopoietin 1 Receptor, Integrin Alpha V, Integrin Beta 3, Melanocortin Receptor 5, Semaphorin 3A, and ADP Ribosylation Factor 6.
Some of the key mechanisms of action of the Diabetic Retinopathy pipeline drugs market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Melanocyte Stimulating Hormone Receptor Agonist, Integrin Alpha V Antagonist, Integrin Beta 3 Antagonist, Melanocortin Receptor 5 Agonist, Semaphorin 3A Inhibitor, ADP Ribosylation Factor 6 Inhibitor, and Angiopoietin 1 Receptor Agonist.
Some of the key routes of administration in the Diabetic Retinopathy pipeline drugs market are intravitreal, oral, ophthalmic, topical, intravenous, intraocular, parenteral, subcutaneous, subconjunctival, and buccal.
The molecule types in the Diabetic Retinopathy pipeline drugs market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, biologic, cell therapy, gene therapy, antisense RNAi oligonucleotide, recombinant protein, and aptamer.
Some of the leading companies in the Diabetic Retinopathy pipeline drugs market are F. Hoffmann-La Roche Ltd, Palatin Technologies Inc, Boehringer Ingelheim International GmbH, PharmAbcine Inc, Regeneron Pharmaceuticals Inc, A6 Pharmaceuticals LLC, Angios GmbH, Ascentage Pharma Group International, Bayer AG, and Charlesson LLC.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Metabolic Disorders reports